class="p">37
David N. Stephens et al., “GABAA Receptor Subtype Involvement in Addictive Behaviour,” Genes, Brain, and Behavior 16, no. 1 (2017), doi:10.1111/gbb.12321.
38
Amanda J. Baxter et al., “The Global Burden of Anxiety Disorders in 2010,” Psychological Medicine 44, no. 11 (2014), doi:10.1017/ S0033291713003243.
39
Debra A. Bangasser et al., “Sex Difef rences in Stress Regulation of Arousal and Cognition,” Physiology and Behavior 187 (2018), doi:10.1016/j.physbeh.2017.09.025.
40
Richard W. Olsen and Jing Liang, “Role of GABAA Receptors in Alcohol Use Disorders Suggested by Chronic Intermittent Ethanol (CIE) Rodent Model,” Molecular Brain 10 (2017), doi:10.1186/ s13041-017-0325-8.
41
Marcus A. Bachhuber et al., “Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996–2013,” American Journal of Public Health 106, no. 4 (2016), doi:10.2105/ AJPH.2016.303061.
42
“Is It Bedtime for Benzos?” Van Winkle’s (blog), The Hufnif gton Post, www.hufifngtonpost.com/van-winkles/is-it-bedtime-forbenzos_b_7663456.html.
43
Charles A. Czeisler, “Perspective: Casting Light on Sleep Deficiency,” Nature, May 23, 2013; Megumi Hatori et al., “Global Rise of Potential Health Hazards Caused by Blue Light – Induced Circadian Disruption in Modern Aging Societies,” NPJ: Aging and Mechanisms of Disease, June 16, 2017, doi:10.1038/s41514-017-0010-2.
44
Samuel H. Zuvekas and Benedetto Vitiello, “Stimulant Medication Use Among U.S. Children: A Twelve-Year Perspective,” American Journal of Psychiatry 169, no. 2 (2012), doi:10.1176/appi. ajp.2011.11030387.
45
Nora D. Volkow, “Long-Term Safety of Stimulant Use for ADHD: Findings from Nonhuman Primates,” Neuropsychopharmacology 37, no. 12 (2012).
46
Daniel Morales Guzmán and Aaron Ettenberg, “Runway SelfAdministration of Intracerebroventricular Cocaine: Evidence of Mixed Positive and Negative Drug Actions,” Behavioral Pharmacology 18, no. 1 (2007).
47
Таблетированный энергетический ненаркотический стимулятор.
48
World No Tobacco Day 2017, “Tobacco Threatens Us All: Protect Health, Reduce Poverty, and Promote Development” (Geneva: World Health Organization, 2017).
49
L. Cinnamon Bidwell et al., “Genome-Wide SNP Heritability of Nicotine Dependence as a Multidimensional Phenotype,” Psychological Medicine 46, no. 10 (2016), doi:10.1017/S0033291716000453.
50
Mariella De Biasi and John A. Dani, “Reward, Addiction, Withdrawal to Nicotine,” Annual Review of Neuroscience 34 (2011), doi:10.1146/ annurevneuro-061010–113734.
51
Aaron Ettenberg, “Opponent Process Properties of Self-Administered Cocaine,” Neuroscience and Biobehavioral Reviews 27, no. 8 (2004).
52
Juan Sanchez-Ramos, “Neurologic Complications of Psychomotor Stimulant Abuse,” in International Review of Neurobiology: The Neuropsychiatric Complications of Stimulant Abuse, ed. Pille Taba, Andrew Lees, and Katrin Sikk (Amsterdam: Academic Press, 2015).
53
G. Hatzidimitriou, U. D. McCann, G. A. Ricaurte, “Altered Serotonin Innervation Patterns in the Forebrain of Monkeys Treated with (±)3,4-Methylenedioxymethamphetamine Seven Years Previously: Factors Influencing Abnormal Recovery,” Journal of Neuroscience 19 (1989): 5096–5107.
54
Lynn Taurah, Chris Chandler, Geoff Sanders, “Depression, Impulsiveness, Sleep, and Memory in Past and Present Polydrug Users of 3,4-Methylene dioxymethamphetamine (MDMA, ecstasy),” Psychopharmacology 231 (2014), doi:10.1007/s00213-013-3288-1.
55
Albert Hofmann, “Notes and Documents Concerning the Discovery of LSD,” Agents and Actions 1, no. 3 (1970), doi.org/10.1007/ BFO1986673.
56
“Stanislav Grof Interviews Dr. Albert Hofmann, Esalen Institute, Big Sur, California, 1984,” accessed April 14, 2018, www.maps.org.
57
“LSD: The Geek’s Wonder Drug?” www.wired.com, Jan. 16, 2006.
58
Diana Kwon, “Trippy Treatments,” Scientist, Sept. 2017.
59
Michael P. Bogenschutz et al., “Psilocybin-Assisted Treatment for Alcohol Dependence: A Proof-of-Concept Study,” Journal of Psychopharmacology 29, no. 3 (2015), doi:10.1177/0269881114565144.
60
Peter S. Hendricks et al., “The Relationships of Classic Psychedelic Use with Criminal Behavior in the United States Adult Population,” Journal of Psychopharmacology 32, no. 1 (2018), doi:10.1177/0269881117735685.
61
R. R. Grififths et al., “Psilocybin-Occasioned Mystical-Type Experience in Combination With Meditation and Other Spiritual Practices Produces Enduring Positive Changes in Psychological Functioning and in Trait Measures of Prosocial Attitudes and Behaviors,” Journal of Psychopharmacology 32 (2018): 49–69.
62
José Carlos Bouso et al., “Personality, Psychopathology, Life Attitudes, and Neuropsychological Performance Among Ritual Users of Ayahuasca: A Longitudinal Study,” PLoS ONE 7, no. 8 (2012), doi. org/10.1371/journal.pone.0042421.
63
Evan J. Kyzar et al., “Psychedelic Drugs in Biomedicine,” Trends in Pharmacological Science 38, no. 11 (2017).
64
David E. Nichols, Matthew W. Johnson, and Charles D. Nichols, “Psychedelics as Medicines: An Emerging New Paradigm,” Clinical Pharmacology and Therapeutics 101, no. 2 (2017), doi:10.1002/cpt.557
65
Cody J. Wenthur, Bin Zhou, and Kim D. Janda, “Vaccine-Driven Pharmacodynamic Dissection and Mitigation of Fenethylline Psychoactivity,” Nature 548 (2017), doi:10.1038/nature23464.
66
Xin Wang, Zheng Xu, and Chang-Hong Miao, “Current Clinical Evidence on the Efef ct of General Anesthesia on Neurodevelopment in Children: An Updated Systematic Review with Meta-regression,” PLoS ONE 9, no. 1 (2014), doi:10.1371/journal.pone.0085760.
67
Matthew Baggott, E. Erowid, and F. Erowid, “A Survey of Salvia divinorum Users,” Erowid Extracts 6 (June 2004), accessed March 2, 2018.
68
Rachel I. Anderson and Howard C. Becker, “Role of the Dynorphin/ Kappa Opioid Receptor System in the Motivational Efef cts of Ethanol,” Alcoholism: Clinical and Experimental Research 41, no. 8 (2017); George F. Koob, “The Dark Side of Emotion: The Addiction Perspective,” European Journal of Pharmacology 15 (2015).
69
André Cruz et al., “A Unique Natural Selective Kappa-opioid Receptor Agonist, Salvinorin A, and Its Roles in Human Therapeutics,” Phytochemistry 137 (2017), doi:10.1016/j.phytochem.2017.02.001.
70
Yong Zhang et al., “Efef cts of the Plant-Derived Hallucinogen Salvinorin A on Basal Dopamine Levels in the Caudate Putamen and in a Conditioned
